Sponsored Links
| New Findings Demonstrate Potential Benefits Of GATTEX™ (teduglutide) In Phase 3 Study Of Patients With Short Bowel Syndrome |
 |
 |
 |
| Medical News - Irritable-Bowel Syndrome | |||
|
Clinical investigators presented new data from three sub-studies in patients with short bowel syndrome (SBS) who received GATTEX™ (teduglutide) during a 24-week, placebo-controlled Phase 3 clinical trial. Results were presented at the annual Digestive Disease Week (DDW) Congress taking place in Chicago. Read more: Irritable-Bowel Syndrome News From Medical News Today
|